Showing 3771-3780 of 7767 results for "".
- ADmirable Trial: Lebrikizumab Shows Efficacy in AD Among Skin of Color Populationshttps://practicaldermatology.com/news/admirable-lebrikizumab-shows-efficacy-in-ad-among-skin-of-color-populations/2475811/Lebrikizumab significantly improved atopic dermatitis (AD) outcomes in patients with skin of color in the ADmirable phase 3b trial. The ADmirable study, and open-label, 24-week trial evaluating lebrikizumab in patients with F
- Long-Term Ixekizumab Use Not Linked to Increased Cancer Risk: Analysishttps://practicaldermatology.com/news/long-term-ixekizumab-use-not-linked-to-increased-cancer-risk/2475704/Long-term treatment with ixekizumab (IXE) for psoriasis, psoriatic arthritis, and axial spondyloarthritis was not associated with increased risk of malignant neoplasms, according to a new analysis of pooled data from 25 randomized clinical trials.
- LEQSELVI™ Launches in U.S. as Oral Treatment for Severe Alopecia Areatahttps://practicaldermatology.com/news/leqselvitm-launches-in-us-as-oral-treatment-for-severe-alopecia-areata/2475680/Sun Pharmaceutical Industries Ltd. announced the U.S. commercial availability of LEQSELVI™ (deuruxolitinib), an oral Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata, according to a press release from the manufacturer.
- Positive Early Results in Tralokinumab Trial for AD on Handshttps://practicaldermatology.com/news/Positive-Early-Results-Tralokinumab-Trial-AD-Hands/2475575/A trial evaluating tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) on the hands, who are candidates for systemic therapy, met the primary endpoint and all secondary endpoints with a statistically significant improvement in AD on the hands after 16 weeks of
- Meta-Analysis IDs Promising Therapies for Hidradenitis Suppurativahttps://practicaldermatology.com/news/meta-analysis-ids-promising-therapies-for-hidradenitis-suppurativa/2475515/A new network meta-analysis comparing treatments for moderate to severe hidradenitis suppurativa (HS) shows several agents offering significantly improved efficacy over placebo. Researchers reviewed phase 2 and 3 randomized c
- Study: 90% Would Purchase Red Light Therapy Deviceshttps://practicaldermatology.com/news/study-90-would-purchase-red-light-therapy-devices/2475498/New research published in the Journal of Clinical and Aesthetic Dermatology showed how social media is fueling the growing consumer demand for over-the-counter (OTC) red light therapy (RLT) devices. The authors of the
- VISIBLE: Guselkumab Provides Scalp Psoriasis Relief in Diverse Skin Toneshttps://practicaldermatology.com/news/visible-guselkumab-provides-scalp-psoriasis-relief-in-diverse-skin-tones/2475455/Guselkumab 100 mg demonstrated efficacy and sustained improvement through 48 weeks in a cohort of adults with moderate to severe scalp psoriasis and skin of color, new research suggests. In the B cohort of the phase 3b, rand
- SKINVIVE sPMA Accepted for Neck Line Treatmenthttps://practicaldermatology.com/news/skinvive-spma-accepted-for-neck-line-treatment/2475452/The U.S. Food and Drug Administration (FDA) has accepted for review a supplemental premarket approval (sPMA) application from Allergan Aesthetics, an AbbVie company, for SKINVIVE by JUVÉDERM® for the treatment of neck lines in adults, according to a press release.<
- New Data for Lebrikizumab and Tildrakizumab Unveiled at ICD 2025https://practicaldermatology.com/news/new-data-for-lebrikizumab-and-tildrakisumab-unveiled-at-icd-2025/2475320/New real-world and clinical data supporting the use of lebrikizumab in atopic dermatitis (AD) and tildrakizumab in psoriasis was recently presented at the XIV International Congress of Dermatology (ICD) in Rome, according to a press release from Almirall.
- Coverage Decision May Jeopardize Image-guided Skin Cancer Treatment: Reporthttps://practicaldermatology.com/news/medicare-contractors-threaten-coverage-of-noninvasive-skin-cancer-treatment/2475193/Medicare Administrative Contractors (MACs) are proposing to withdraw insurance coverage for image-guided superficial radiation therapy (IGSRT), according to a news letter from SkinCure Oncology. IGSRT is an FDA-cleared, nonin